FY2024 EPS Estimates for Medpace Holdings, Inc. (NASDAQ:MEDP) Increased by Analyst

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities research analysts at William Blair boosted their FY2024 earnings estimates for shares of Medpace in a research report issued on Tuesday, April 23rd. William Blair analyst M. Smock now anticipates that the company will post earnings of $11.07 per share for the year, up from their previous forecast of $10.55. The consensus estimate for Medpace’s current full-year earnings is $11.13 per share. William Blair also issued estimates for Medpace’s Q1 2025 earnings at $3.33 EPS and FY2025 earnings at $12.87 EPS.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same period in the previous year, the company posted $2.27 EPS. Medpace’s revenue was up 17.7% on a year-over-year basis.

Several other equities research analysts have also issued reports on MEDP. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their price objective for the company from $340.00 to $450.00 in a research note on Tuesday. Guggenheim boosted their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Medpace Stock Down 2.4 %

Medpace stock opened at $397.56 on Thursday. Medpace has a 12 month low of $189.30 and a 12 month high of $421.00. The company’s fifty day simple moving average is $397.84 and its 200-day simple moving average is $323.66. The stock has a market cap of $12.32 billion, a P/E ratio of 40.53, a P/E/G ratio of 2.04 and a beta of 1.38.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC bought a new stake in Medpace in the first quarter valued at about $27,000. Mather Group LLC. bought a new stake in Medpace during the first quarter worth about $28,000. Contravisory Investment Management Inc. bought a new stake in Medpace during the fourth quarter worth about $26,000. RiverPark Advisors LLC bought a new stake in Medpace during the fourth quarter worth about $26,000. Finally, Arcadia Investment Management Corp MI grew its stake in Medpace by 40.3% during the first quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock worth $41,000 after buying an additional 29 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Activity

In other news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,340 shares of company stock valued at $76,651,647. Insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.